Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02564744
Title Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Debiopharm International SA

marginal zone B-cell lymphoma

MALT lymphoma

mantle cell lymphoma

diffuse large B-cell lymphoma

follicular lymphoma


Naratuximab Emtansine + Rituximab

Age Groups: adult | senior
Covered Countries USA | ITA | BEL

No variant requirements are available.